Breast cancer is the most common cancer in women in the U.S., excludingskin cancers, and is the second leading cause of cancer death in women, though deaths have steadily declined due to earlier detection through screenings and better treatment options. The earlier breast cancer is detected, ...
Food & Drug Administration (FDA) approved Faslodex, or fulvestrant, for the treatment of hormone receptor positive metastatic breast cancer in post-menopausal women whose disease progresses following anti-estrogen therapy. Way that estrogen can stimulate the growth of tumors; Effectiveness of the drug;...
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation, the FDA said on Friday. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. "This class of drugs has been used to...
Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1376, 1988. PubMed Google Scholar Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen-receptor-negati...
11 suggest new treatment options in advanced breast cancer refractory to conventional chemotherapy. A double-blind crossover trial showed that anastrozole (ARI) should be given as first-line adjuvant therapy with tamoxifen (TAM) used after first progression for women with advanced breast cancer. ...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapie...
Another group's different ACSS2-inhibiting approach is inhuman clinical trials, and Schug's research shows how ACSS2-inhibiting treatment might be able to improve outcomes for patients diagnosed with the infamous TNBC. By testing ACSS2 inhibitors alongside standard anti-breast-cancer chemotherapy, Sch...
These findings suggest promising treatment options while raising important questions about which subgroups would benefit most. Dr Armaghani notes that the discussions and questions sparked by these studies are expected to continue and evolve.
Triple-negative breast cancer (TNBC) remains the most aggressive cluster of all breast cancers, which is due to its rapid progression, high probabilities of early recurrence, and distant metastasis resistant to standard treatment. Following the advances in cancer genomics and transcriptomics that can ...
{EUROPEAN JOURNAL OF CANCER}, issn = {0959-8049}, language = {eng}, pages = {S90-S90}, publisher = {PERGAMON-ELSEVIER SCIENCE LTD}, title = {A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the combined hormonal agent trialists group (CHAT)}, volume...